Table 1 Comparison of anthropometric and blood test measurements in individuals receiving or not receiving levothyroxine replacement during the first and last visit

Weight, kg

104 (94–118)

98 (91–112)

<.001

101 (94–118)

97 (89–110)

<.001

.731

.566

BMI, kg/m²

37.8 (36.0–42.1)

36.5 (35.1–39.4)

<.001

38.7 (36.2–43.3)

37.2 (34.8–40.9)

<.001

.198

.377

BFP (%), men

35.6 (32.1–38.0)

33.4 (30.5–36.0)

<.001

38.0(34.2–43.3)

35.9 (32.0–41.4)

.022

.111

.221

BFP (%), women

45.7 (43.7–48.9)

44.4 (42.6–47.0)

<.001

46.2 (42.8–49.2)

44.7 (42.0–47.4)

<.001

.688

.597

TSH (μIU/L)

1.2 (0.9–1.6)

1.2 (0.9–1.6)

.841

2.2 (1.6–2.7)

1.3 (0.9–2.0)

<.001

<.001

.113

fT4 (pmol/L)

13.3 (12.4–14.5)

13.4 (12.4–14.7)

.520

12.7 (11.6–13.8)

14.0 (12.8–15.1)

<.001

.001

.017

fT3 (pmol/L)

4.3 (3.9–4.7)

4.3 (4.0–4.9)

.020

4.2 (3.8–4.8)

4.2 (3.9–4.6)

.412

.550

.083

SPINA-GD (nmol/s)

30 (26–33)

30 (27–35)

.012

31 (26–35)

28 (24–32)

<.001

.183

.004

SPINA-GT (pmol/s)

3.6 (2.8–4.3)

3.4 (2.7–4.4)

.419

–

–

–

–

–

Calcium (mg/dL)

9.2 (8.9–9.4)

9.6 (9.3–9.8)

<.001

9.1 (8.8–9.4)

9.5 (9.1–9.7)

<.001

.114

.094

Phosphorus (mg/dL)

3.3 (3.1–3.7)

3.5 (3.2–3.8)

<.001

3.5 (3.1–3.8)

3.6 (3.1–3.8)

.066

.133

.497

Parathormone (pg/mL)

72 (56–103)

67 (48–89)

.001

67 (49–91)

65 (52–83)

.045

.427

.984

25(OH)D (nmol/L)

36 (24–48)

53 (41–69)

<.001

31 (21–49)

56 (40–69)

<.001

.266

.705